New Delhi, Beritasatu.com– The New Delhi City Authority in India has reported more than 1,000 cases of black fungus amid a shortage of drugs to treat Covid-19. As reported RT, Thursday (3/6/2021), the number of cases of so-called black fungus, or mucormycosis, nearly doubled in Delhi over the past week, with 1,044 infections.
Local authorities say the disease specifically affects Covid patients in India. A further 440 people have been diagnosed in the city since last week, when the number of afflicted patients reached 600.
On Thursday (3/6), Health Minister Satyendra Jain said that 89 people had died from the disease in Delhi to date. While 92 others have recovered.
“Lack of medicine to treat mucormycosis is still a problem for the city of 29 million,” the minister added.
Black mold cases have been on the rise in India during the harsh second wave of the coronavirus pandemic. As of May 25, the country saw 11,700 infections, which prompted several states to declare mucormycosis an epidemic. The condition explains that the health authorities do not have sufficient quantities of the antifungal drug Amphotericin B for the number of patients.
Due to the weakened immune system in people with Covid, the fungus most often enters the human body through the nose and mouth before spreading to the lungs, heart, or brain. Symptoms of this fungus include facial swelling and black lesions – true to its name – and it has a mortality rate of around 54%.
Spike in black mold incidence among virus patients corona India is mostly associated with steroids and anti-inflammatory drugs prescribed during their treatment for Covid-19.
While helping to save lives, the drugs also weaken the immune system, making it more difficult to fight off the spores. Another factor is believed to be the high number of people with uncontrolled diabetes in India, as patients with this condition often suffer from the most severe form of mucormycosis.